Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus

This study aimed to indicate whether autologous bone marrow cell infusion (ABMI) via the right omental vein (ROV) could have a regulatory effect on decompensated liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this purpose, 24 DLC patients with T2DM were divided into observa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Baochi Liu, Mingrong Cheng, Lin Lang, Lei Li, Yanhui Si, Guangmian Wang
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	autologous bone marrow infusion decompensated cirrhosis type 2 diabetes cell therapy surgery-related complications Physiology QP1-981
Acceso en línea:	https://doaj.org/article/058bde326aaf4c05a60d97ed690c01eb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:058bde326aaf4c05a60d97ed690c01eb
record_format	dspace
spelling	oai:doaj.org-article:058bde326aaf4c05a60d97ed690c01eb2021-11-18T09:14:51ZAutologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus1664-042X10.3389/fphys.2021.730797https://doaj.org/article/058bde326aaf4c05a60d97ed690c01eb2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphys.2021.730797/fullhttps://doaj.org/toc/1664-042XThis study aimed to indicate whether autologous bone marrow cell infusion (ABMI) via the right omental vein (ROV) could have a regulatory effect on decompensated liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this purpose, 24 DLC patients with T2DM were divided into observation group (n=14) and control group (n=10). Patients in the observation group were given ABMI through the ROV and right omental artery (ROA), and cases in the control group received ABMI through the ROV. At 1, 3, 6, and 12months after ABMI, it was revealed that the prothrombin time, the total bilirubin levels, and the amount of ascites were significantly lower, while the serum albumin levels in the two groups were markedly higher compared with those before ABMI (p<0.01), and there was no significant difference between the two groups at each time point (p>0.05). The fasting blood glucose and glycosylated hemoglobin levels at 6 and 12months after ABMI in the two groups significantly decreased compared with those before ABMI (p<0.05 or p<0.01), while the decreased levels in the observation group were more obvious than those in the control group at each time point (p<0.01). The amount of insulin in the observation group at 3, 6, and 12months after ABMI was significantly less than that before ABMI in the control group (p<0.01). In summary, ABMI showed a significant therapeutic efficacy for DLC patients with T2DM through ROV and ROA.Baochi LiuMingrong ChengMingrong ChengLin LangLei LiYanhui SiGuangmian WangFrontiers Media S.A.articleautologous bone marrow infusiondecompensated cirrhosistype 2 diabetescell therapysurgery-related complicationsPhysiologyQP1-981ENFrontiers in Physiology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	autologous bone marrow infusion decompensated cirrhosis type 2 diabetes cell therapy surgery-related complications Physiology QP1-981
spellingShingle	autologous bone marrow infusion decompensated cirrhosis type 2 diabetes cell therapy surgery-related complications Physiology QP1-981 Baochi Liu Mingrong Cheng Mingrong Cheng Lin Lang Lei Li Yanhui Si Guangmian Wang Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
description	This study aimed to indicate whether autologous bone marrow cell infusion (ABMI) via the right omental vein (ROV) could have a regulatory effect on decompensated liver cirrhosis (DLC) patients with type 2 diabetes mellitus (T2DM). For this purpose, 24 DLC patients with T2DM were divided into observation group (n=14) and control group (n=10). Patients in the observation group were given ABMI through the ROV and right omental artery (ROA), and cases in the control group received ABMI through the ROV. At 1, 3, 6, and 12months after ABMI, it was revealed that the prothrombin time, the total bilirubin levels, and the amount of ascites were significantly lower, while the serum albumin levels in the two groups were markedly higher compared with those before ABMI (p<0.01), and there was no significant difference between the two groups at each time point (p>0.05). The fasting blood glucose and glycosylated hemoglobin levels at 6 and 12months after ABMI in the two groups significantly decreased compared with those before ABMI (p<0.05 or p<0.01), while the decreased levels in the observation group were more obvious than those in the control group at each time point (p<0.01). The amount of insulin in the observation group at 3, 6, and 12months after ABMI was significantly less than that before ABMI in the control group (p<0.01). In summary, ABMI showed a significant therapeutic efficacy for DLC patients with T2DM through ROV and ROA.
format	article
author	Baochi Liu Mingrong Cheng Mingrong Cheng Lin Lang Lei Li Yanhui Si Guangmian Wang
author_facet	Baochi Liu Mingrong Cheng Mingrong Cheng Lin Lang Lei Li Yanhui Si Guangmian Wang
author_sort	Baochi Liu
title	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
title_short	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
title_full	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
title_fullStr	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
title_full_unstemmed	Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus
title_sort	autologous bone marrow cell infusion for the treatment of decompensated liver cirrhosis patients with type 2 diabetes mellitus
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/058bde326aaf4c05a60d97ed690c01eb
work_keys_str_mv	AT baochiliu autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT mingrongcheng autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT mingrongcheng autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT linlang autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT leili autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT yanhuisi autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus AT guangmianwang autologousbonemarrowcellinfusionforthetreatmentofdecompensatedlivercirrhosispatientswithtype2diabetesmellitus
_version_	1718420943733260288

Autologous Bone Marrow Cell Infusion for the Treatment of Decompensated Liver Cirrhosis Patients With Type 2 Diabetes Mellitus

Ejemplares similares